Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Stopped early · Phase 1
Conditions studied: Acute Myelogenous Leukemia (AML)
In brief
The main purpose of this study are to determine the maximum dose of AT-406 that can be safely given in combination with cytarabine and daunorubicin to humans. Other purposes are to determine how the drug is broken down in the body, and to see if there are any molecular interactions that can help determine how AT-406 works. Side effects will also be studied in an effort to make sure that this drug is safe to take.
Key facts
- Study ID
- NCT01265199
- Run by
- Ascenta Therapeutics
- People needed
- 29
- Starts
- 2011-02-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2013-01-23
Who can join
Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Univerity of Chicago — Chicago, Illinois, United States
- University of Michigan Health System — Ann Arbor, Michigan, United States
- Washington University at St. Louis Siteman Cancer Center — St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Temple University at Jeanes Hospital — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.